PH17510A - Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen,antibody and methods - Google Patents

Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen,antibody and methods

Info

Publication number
PH17510A
PH17510A PH24938A PH24938A PH17510A PH 17510 A PH17510 A PH 17510A PH 24938 A PH24938 A PH 24938A PH 24938 A PH24938 A PH 24938A PH 17510 A PH17510 A PH 17510A
Authority
PH
Philippines
Prior art keywords
antibody
monoclonal antibody
cell line
antigen
methods
Prior art date
Application number
PH24938A
Other languages
English (en)
Inventor
Patrick Chung-Shu Kung
Gideon Goldstein
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH17510(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of PH17510A publication Critical patent/PH17510A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hybrid Cells (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH24938A 1979-12-04 1980-12-03 Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen,antibody and methods PH17510A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/100,072 US4364935A (en) 1979-12-04 1979-12-04 Monoclonal antibody to a human prothymocyte antigen and methods of preparing same

Publications (1)

Publication Number Publication Date
PH17510A true PH17510A (en) 1984-09-07

Family

ID=22277974

Family Applications (1)

Application Number Title Priority Date Filing Date
PH24938A PH17510A (en) 1979-12-04 1980-12-03 Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen,antibody and methods

Country Status (22)

Country Link
US (1) US4364935A (en])
EP (1) EP0030815B1 (en])
JP (2) JPS5695123A (en])
AT (1) ATE13317T1 (en])
AU (1) AU545223B2 (en])
CA (1) CA1183470A (en])
DE (2) DE30815T1 (en])
DK (1) DK153954C (en])
ES (1) ES8303097A1 (en])
FI (1) FI75365C (en])
GR (1) GR72923B (en])
HK (1) HK24386A (en])
IE (1) IE50725B1 (en])
IL (1) IL61624A (en])
MY (1) MY8600519A (en])
NO (1) NO159888C (en])
NZ (1) NZ195647A (en])
PH (1) PH17510A (en])
PT (1) PT72146B (en])
SG (1) SG7386G (en])
YU (1) YU45078B (en])
ZA (1) ZA807567B (en])

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806349A (en) * 1979-12-04 1989-02-21 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
JPS5823847B2 (ja) * 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
EP0103632B1 (en) * 1982-03-15 1990-12-19 The Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US4705687A (en) * 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US6498006B2 (en) 1997-11-24 2002-12-24 Johnson T. Wong Methods for treatment of HIV and other infections using A T cell or viral activator and anti-retroviral combination therapy
FR2878852B1 (fr) * 2000-09-28 2007-02-23 Imtix Sangstat Procede de production d'immunoglobulines anti-thymocytes humains
US7653260B2 (en) 2004-06-17 2010-01-26 Carl Zeis MicroImaging GmbH System and method of registering field of view
US8582924B2 (en) 2004-06-30 2013-11-12 Carl Zeiss Microimaging Gmbh Data structure of an image storage and retrieval system
JP5496669B2 (ja) * 2006-09-01 2014-05-21 ジェンティセル リンパ除去化合物、および抗原配列を含みかつプロフェッショナル抗原提示細胞をターゲットとする分子を含んでなる、特異的ｃｔｌ応答を誘発する組成物
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3104882B1 (en) 2014-02-14 2019-06-05 Centrose, Llc Extracellular targeted drug conjugates
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
CN107207610B (zh) 2014-11-26 2022-09-09 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MX2017006918A (es) 2014-11-26 2018-01-25 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38.
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
AU2017290086A1 (en) 2016-06-28 2019-01-24 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2017342560B2 (en) 2016-10-14 2022-03-17 Xencor, Inc. IL15/IL15Ralpha heterodimeric Fc-fusion proteins
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
KR20210069641A (ko) 2018-10-03 2021-06-11 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
BR112021016955A2 (pt) 2019-03-01 2021-11-23 Xencor Inc Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2022192403A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CN114085818A (zh) * 2021-11-19 2022-02-25 蔡开来 一种抗大熊猫Thy1单克隆抗体及其杂交瘤细胞株和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
AU545223B2 (en) 1985-07-04
HK24386A (en) 1986-04-11
JPS6413988A (en) 1989-01-18
MY8600519A (en) 1986-12-31
ES8303097A1 (es) 1983-02-16
IE802511L (en) 1981-06-04
EP0030815B1 (en) 1985-05-15
ZA807567B (en) 1982-07-28
FI803757L (fi) 1981-06-05
NO159888B (no) 1988-11-07
CA1183470A (en) 1985-03-05
ATE13317T1 (de) 1985-06-15
DK153954C (da) 1989-02-20
ES497425A0 (es) 1982-12-16
NO803661L (no) 1981-06-05
GR72923B (en]) 1984-01-11
EP0030815A3 (en) 1981-12-30
IE50725B1 (en) 1986-06-25
DE30815T1 (de) 1984-07-19
JPS649999B2 (en]) 1989-02-21
YU306780A (en) 1984-04-30
FI75365B (fi) 1988-02-29
NO159888C (no) 1989-02-15
PT72146B (en) 1982-07-05
US4364935A (en) 1982-12-21
PT72146A (en) 1981-01-01
JPS5695123A (en) 1981-08-01
AU6501280A (en) 1981-06-11
SG7386G (en) 1986-11-21
DK153954B (da) 1988-09-26
DE3070655D1 (en) 1985-06-20
FI75365C (fi) 1988-06-09
JPH0159870B2 (en]) 1989-12-20
DK517380A (da) 1981-06-05
YU45078B (en) 1992-03-10
EP0030815A2 (en) 1981-06-24
NZ195647A (en) 1984-07-06
IL61624A0 (en) 1981-01-30
IL61624A (en) 1984-07-31

Similar Documents

Publication Publication Date Title
PH17510A (en) Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen,antibody and methods
DE3170352D1 (en) Hybrid cell line for producing monoclonal antibody to a human t cell antigen, antibody, and methods
ZA802524B (en) Hybrid cell line for producing monoclonal antibody to human helper t cells,antibody,and methods
ZA801604B (en) Hybrid cell line for producing monoclonal antibody to human t cells, antibody, and methods
YU306580A (en) Process for obtaining a monoclonal antibody
YU45077B (en) Process for obtaining a monoclonal antibody
ZA807564B (en) Hybird cell line for producing monoclonal antibody to a human thymocyte antigen,antibody,and methods

Legal Events

Date Code Title Description
AT Record of annual fee payments

Year of fee payment: 12